Literature DB >> 20214205

Therapeutic influence of 20 % albumin versus 6% hydroxyethylstarch on extravascular lung water in septic patients: a randomized controlled trial.

Martin Dolecek1, Petr Svoboda, Ilona Kantorová, Peter Scheer, Igor Sas, Jitka Bíbrová, Jana Radvanova, Martin Radvan.   

Abstract

BACKGROUND/AIMS: Recent studies demonstrated that extravascular lung water (EVLW) is a reliable and independent marker for outcome. The primary therapeutically goal in critically ill patients is to resuscitate and retain adequate organ perfusion by fluid administration, where is necessary to achieve adequate intravascular filling, but avoid initiation of pulmonary edema.
METHODOLOGY: Patients with severe sepsis were randomly allocated to a group treated with 20% Albumin 100 ml every 12 hours (ALB; n = 30) or with 6% hydroxyethylstarch 130/0, 4 250 ml every 6 hours (HES; n = 26). Both treatments were completed by crystalloids or norephinephrin as necessary. We analyzed amount of developed EVLW, and relation with mortality, PaO2/FiO2 and alveolo-arterial oxygen difference.
RESULTS: We observed significantly greater decrease of EVLW when compared with baseline during whole monitored period of 72 hours in ALB group in contrast to HES patients (p < 0.05). Despite no significant changes of EVLW in HES group, we noted improve of PaO2/FiO2 and AaDO2 in both groups. We did not observed significant difference in mortality.
CONCLUSION: The present study results show can summarize that albumin reduces in a higher amount and earlier the extravascular lung water than HES, but this reduction was not associated with improvement of oxygenation functions, which was better in HES group.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20214205

Source DB:  PubMed          Journal:  Hepatogastroenterology        ISSN: 0172-6390


  14 in total

1.  "Colloid twice daily" is not fluid resuscitation! Inappropriate inclusion of clinical trials in meta-analyses may distract from gaps in evidence.

Authors:  Peter Kranke; Norbert Roewer; Ralf M Muellenbach
Journal:  Intensive Care Med       Date:  2013-06-05       Impact factor: 17.440

Review 2.  Randomised trials of 6% tetrastarch (hydroxyethyl starch 130/0.4 or 0.42) for severe sepsis reporting mortality: systematic review and meta-analysis.

Authors:  Amit Patel; Umeer Waheed; Stephen J Brett
Journal:  Intensive Care Med       Date:  2013-02-22       Impact factor: 17.440

Review 3.  Fluid replacement with hydroxyethyl starch in critical care--a reassessment.

Authors:  Christiane S Hartog; Tobias Welte; Peter Schlattmann; Konrad Reinhart
Journal:  Dtsch Arztebl Int       Date:  2013-06-28       Impact factor: 5.594

4.  Development of a Physiologically Based Pharmacokinetic Modelling Approach to Predict the Pharmacokinetics of Vancomycin in Critically Ill Septic Patients.

Authors:  Christian Radke; Dagmar Horn; Christian Lanckohr; Björn Ellger; Michaela Meyer; Thomas Eissing; Georg Hempel
Journal:  Clin Pharmacokinet       Date:  2017-07       Impact factor: 6.447

Review 5.  Colloid solutions for fluid resuscitation.

Authors:  Frances Bunn; Daksha Trivedi
Journal:  Cochrane Database Syst Rev       Date:  2012-07-11

Review 6.  Fluid resuscitation with 6 % hydroxyethyl starch (130/0.4 and 130/0.42) in acutely ill patients: systematic review of effects on mortality and treatment with renal replacement therapy.

Authors:  David J Gattas; Arina Dan; John Myburgh; Laurent Billot; Serigne Lo; Simon Finfer
Journal:  Intensive Care Med       Date:  2013-02-14       Impact factor: 17.440

7.  Harm associated with 6 % tetrastarch 130 kDa [hydroxyethyl starch (HES) 130/0.4 and 130/0.42] is robust to sensitivity analysis by excluding Dolecek et al.

Authors:  Amit Patel; Umeer Waheed; Stephen J Brett
Journal:  Intensive Care Med       Date:  2013-06-05       Impact factor: 17.440

Review 8.  Hydroxyethyl starch 130/0.38-0.45 versus crystalloid or albumin in patients with sepsis: systematic review with meta-analysis and trial sequential analysis.

Authors:  Nicolai Haase; Anders Perner; Louise Inkeri Hennings; Martin Siegemund; Bo Lauridsen; Mik Wetterslev; Jørn Wetterslev
Journal:  BMJ       Date:  2013-02-15

Review 9.  Relative survival benefit and morbidity with fluids in severe sepsis - a network meta-analysis of alternative therapies.

Authors:  M Bansal; A Farrugia; S Balboni; G Martin
Journal:  Curr Drug Saf       Date:  2013-09

10.  Albumin versus other fluids for fluid resuscitation in patients with sepsis: a meta-analysis.

Authors:  Libing Jiang; Shouyin Jiang; Mao Zhang; Zhongjun Zheng; Yuefeng Ma
Journal:  PLoS One       Date:  2014-12-04       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.